The estimated Net Worth of Christopher Ryan Sullivan is at least $23.6 Thousand dollars as of 10 December 2020. Mr. Sullivan owns over 5,095 units of Cerecor Inc stock worth over $23,584 and over the last 4 years he sold CERC stock worth over $0. In addition, he makes $0 as Interim Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer at Cerecor Inc.
Christopher has made over 2 trades of the Cerecor Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 5,095 units of CERC stock worth $11,617 on 10 December 2020.
The largest trade he's ever made was buying 5,095 units of Cerecor Inc stock on 10 December 2020 worth over $11,617. On average, Christopher trades about 2,683 units every 61 days since 2020. As of 10 December 2020 he still owns at least 8,049 units of Cerecor Inc stock.
You can see the complete history of Mr. Sullivan stock trades at the bottom of the page.
Christopher Sullivan serves as Interim Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer of the Company. Mr. Sullivan brings to the Company his strong technical and SEC reporting background, along with his wealth of financial knowledge, including experience with multiple forms of capital raises, based on leading accounting and finance functions at various health sciences, biotech and pharmaceutical companies. Prior to being named the Company’s Interim Chief Financial Officer, Mr. Sullivan was the Vice President of Finance at the Company and served various other escalating roles since joining the Company in April 2018. Prior to joining the Company, Mr. Sullivan was the Corporate Controller for Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) from August 2017 through April 2018, when it was merged with Mallinckrodt in a $1.2 billion transaction. From November 2015 through August 2017, Mr. Sullivan was the Corporate Controller for OpGen Inc. (NASDAQ: OPGN), a microbial genetics analysis company, and prior to that was a Senior Manager at Ernst & Young, LLP where he was employed from August 2005 through October 2015. Mr. Sullivan received his B.S. degrees in Accounting and Finance from the University of Maryland, College Park and is a Certified Public Accountant.
Christopher Sullivan is 36, he's been the Interim Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer of Cerecor Inc since 2020. There are 10 older and no younger executives at Cerecor Inc. The oldest executive at Cerecor Inc is Sol Barer, 72, who is the Chairman of the Board.
Christopher's mailing address filed with the SEC is C/O CERECOR INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE, MD, 20850.
Over the last 9 years, insiders at Cerecor Inc have traded over $0 worth of Cerecor Inc stock and bought 18,463,844 units worth $43,946,959 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Capital, Llc Armistice Capi.... On average, Cerecor Inc executives and independent directors trade stock every 19 days with the average trade being worth of $601,142. The most recent stock trade was executed by Capital, Llc Armistice Capi... on 16 August 2021, trading 50,000 units of CERC stock currently worth $138,000.
Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn's disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease (adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.
Cerecor Inc executives and other stock owners filed with the SEC include: